Vaccinology capacity building in Europe for innovative platforms serving emerging markets

Hendriks, J.; Holleman, Marit; Hamidi, Ahd; Beurret, Michel; Boog, Claire J. P.

doi:10.4161/hv.23163

Cited by 12 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, some training courses on these aspects have been organized by WHO, also in collaboration with both public and private institutions ( 7 , 8 ). In addition, as part of the ADITEC project funded by the European Commission ( 9 ), the WHO and the University of Lausanne organized various theoretical and practical 1-week courses in “Adjuvants and vaccine formulations” with the objective of training students on production, purification, characterization, and control of recombinant antigens, and on methods of preparation of adjuvants, including oil-in-water emulsions and aluminum gels, their formulation with antigens, and quality control of the resulting vaccines.…”

Section: Discussionmentioning

confidence: 99%

Education in Vaccinology: An Important Tool for Strengthening Global Health

Lambert

Podda

2018

Front. Immunol.

View full text Add to dashboard Cite

Over the past 20 years, education of scientists and public health professionals in Vaccinology has increased dramatically. There are now many international, regional, and national courses that provide education in vaccinology. The proliferation of these courses and the high number of applications submitted demonstrate the increasing and continuous need for improved education in this field since, generally, comprehensive vaccinology training is not offered to medical and/or biological sciences students as part of their Universities courses and consequently there is insufficient knowledge of vaccine topics among health-care providers. Multidisciplinary vaccinology courses have not only educational purposes but they may also contribute to strengthening the development, testing, and use of vaccines, which remain the most efficient tool for infectious disease prevention. The courses available have a varied focus and prioritize topics based on the trainees’ different levels of professional exposure and requirements. Overall, they might be classified in two key categories: (i) courses targeting students who, after their university studies in Medicine, Biology, etc., develop a strong interest in vaccines, would like to learn more about the various aspects of vaccinology, and potentially develop a career in this field (postgraduate courses); (ii) courses targeting postdoctoral professionals, who already have a sufficiently broad knowledge of vaccinology, but would like to develop stronger skills to be able to play a leading role in decision-making for vaccine development (advanced professional courses). Both postgraduate and professional courses are available and are based on comprehensive curricula. In the future, particular attention should be paid to include in the training curricula topics that might help vaccine development, efficient and sustainable vaccine introduction through epidemiologically sound vaccination programs, and best practices to address associated challenges, including vaccine hesitancy which could become a threat to successful implementation of vaccination programs, particularly in developed countries. In addition, it appears that the next phase of vaccinology training could benefit from a global and more structured platform that could facilitate exchanges and collaboration and amplify the current capacity for disseminating vaccine education for future vaccinology leaders around the world. This would be favored by synergizing the efforts currently devoted to vaccinology education. To initiate this process of analysis and systematization, a multinational effort is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Education in Vaccinology: An Important Tool for Strengthening Global Health

Lambert

Podda

2018

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The production capacities of DCVMN for EPI vaccines are expected to play a significant role in DoV objectives of further increasing the coverage of measles, polio, rubella and DTP vaccines in resource‐poor countries. These achievements of DCVMN are also attributed to the support partner organizations such as WHO, Netherlands Vaccine Institute, UNICEF, PAHO, Bill & Melinda Gates Foundation, PATH, National Institute for Biological Standards and Control (NIBSC), CDC Atlanta, Sabin Vaccine Institute and CBER, which led to capacity building of member manufacturers . The network itself has strengthened the capacity of manufacturers by facilitating information sharing, encouraging technology transfer activities and representing the manufacturers at various international forums.…”

Section: Discussion and Perspectives For The Futurementioning

confidence: 99%

Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices

Jadhav

Gautam

Gairola

2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Vaccines represent one of the greatest achievements of science and medicine in the fight against infectious diseases. Vaccination is one of the most cost-effective public health tools to prevent infectious diseases. Significant progress has been made in expanding the coverage of vaccines globally, resulting in the prevention of more than two million deaths annually. In 2010, nearly 200 countries endorsed a shared vision to extend the benefits of vaccines to every person by 2020, known as the Decade of Vaccine Initiative (DoV). Vaccine manufacturers in developing countries, as represented by the Developing Countries Vaccine Manufacturers Network (DCVMN), make a significant contribution to DoV by supplying quality vaccines at affordable prices to the people who need them most. About 70% of the global Expanded Program on Immunization (EPI) vaccine supplies are met by DCVMN. Besides EPI vaccine supplies, DCVMN is also targeting vaccines against rotavirus, Japanese encephalitis, pneumonia, human papillomavirus, meningitis and neglected tropical diseases. This article reviews the roles and contributions of DCVMN in making the vaccines accessible and affordable to all.

show abstract

“…The existing large Contract Manufacturing Organisations (CMOs) cater for larger projects and potential blockbusters, leaving the small biotech and academic researchers with few options. There is thus a need to create manufacturing capacity both in Europe as well as LMICs to accommodate such needs [69].…”

Section: Capacity Building In Gmp Manufacturingmentioning

confidence: 99%